vs

Side-by-side financial comparison of COFFEE HOLDING CO INC (JVA) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $27.7M, roughly 1.3× COFFEE HOLDING CO INC). COFFEE HOLDING CO INC runs the higher net margin — 2.9% vs -304.2%, a 307.2% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 30.8%). COFFEE HOLDING CO INC produced more free cash flow last quarter ($265.4K vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 19.2%).

Black Rifle Coffee Company (BRCC) is a coffee company based in Salt Lake City, Utah, United States. Founded in 2014 by former U.S. Army Green Beret Evan Hafer, it gained national attention in 2017 after pledging to hire 10,000 veterans in response to Starbucks's pledge to hire 10,000 refugees.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

JVA vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.3× larger
RXRX
$35.5M
$27.7M
JVA
Growing faster (revenue YoY)
RXRX
RXRX
+650.9% gap
RXRX
681.7%
30.8%
JVA
Higher net margin
JVA
JVA
307.2% more per $
JVA
2.9%
-304.2%
RXRX
More free cash flow
JVA
JVA
$47.6M more FCF
JVA
$265.4K
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
19.2%
JVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
JVA
JVA
RXRX
RXRX
Revenue
$27.7M
$35.5M
Net Profit
$811.5K
$-108.1M
Gross Margin
8.5%
59.8%
Operating Margin
2.8%
-304.8%
Net Margin
2.9%
-304.2%
Revenue YoY
30.8%
681.7%
Net Profit YoY
-35.7%
39.6%
EPS (diluted)
$0.15
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JVA
JVA
RXRX
RXRX
Q4 25
$27.7M
$35.5M
Q3 25
$23.9M
$5.2M
Q2 25
$23.3M
$19.2M
Q1 25
$21.3M
$14.7M
Q4 24
$21.2M
$4.5M
Q3 24
$18.8M
$26.1M
Q2 24
$19.0M
$14.4M
Q1 24
$19.5M
$13.8M
Net Profit
JVA
JVA
RXRX
RXRX
Q4 25
$811.5K
$-108.1M
Q3 25
$-1.2M
$-162.3M
Q2 25
$644.1K
$-171.9M
Q1 25
$1.2M
$-202.5M
Q4 24
$1.3M
$-178.9M
Q3 24
$626.8K
$-95.8M
Q2 24
$-21.8K
$-97.5M
Q1 24
$351.0K
$-91.4M
Gross Margin
JVA
JVA
RXRX
RXRX
Q4 25
8.5%
59.8%
Q3 25
12.2%
-183.8%
Q2 25
18.9%
-4.9%
Q1 25
26.9%
-48.0%
Q4 24
23.2%
-181.4%
Q3 24
20.9%
53.7%
Q2 24
19.5%
36.2%
Q1 24
17.8%
19.1%
Operating Margin
JVA
JVA
RXRX
RXRX
Q4 25
2.8%
-304.8%
Q3 25
-4.6%
-3327.6%
Q2 25
3.8%
-916.8%
Q1 25
7.5%
-1297.9%
Q4 24
8.0%
-4042.4%
Q3 24
3.8%
-377.1%
Q2 24
-0.4%
-697.4%
Q1 24
3.2%
-698.4%
Net Margin
JVA
JVA
RXRX
RXRX
Q4 25
2.9%
-304.2%
Q3 25
-5.0%
-3135.3%
Q2 25
2.8%
-894.2%
Q1 25
5.4%
-1373.3%
Q4 24
5.9%
-3935.5%
Q3 24
3.3%
-367.5%
Q2 24
-0.1%
-676.6%
Q1 24
1.8%
-662.4%
EPS (diluted)
JVA
JVA
RXRX
RXRX
Q4 25
$0.15
$-0.17
Q3 25
$-0.21
$-0.36
Q2 25
$0.11
$-0.41
Q1 25
$0.20
$-0.50
Q4 24
$0.22
$-0.56
Q3 24
$0.11
$-0.34
Q2 24
$0.00
$-0.40
Q1 24
$0.06
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JVA
JVA
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$701.9K
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$27.6M
$1.1B
Total Assets
$42.0M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JVA
JVA
RXRX
RXRX
Q4 25
$701.9K
$743.3M
Q3 25
$979.8K
$659.8M
Q2 25
$1.8M
$525.1M
Q1 25
$2.4M
$500.5M
Q4 24
$1.4M
$594.4M
Q3 24
$3.1M
$427.6M
Q2 24
$2.4M
$474.3M
Q1 24
$2.4M
$296.3M
Total Debt
JVA
JVA
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
JVA
JVA
RXRX
RXRX
Q4 25
$27.6M
$1.1B
Q3 25
$26.8M
$1.0B
Q2 25
$28.0M
$919.1M
Q1 25
$27.3M
$933.9M
Q4 24
$26.2M
$1.0B
Q3 24
$24.9M
$524.6M
Q2 24
$24.3M
$584.4M
Q1 24
$24.3M
$401.2M
Total Assets
JVA
JVA
RXRX
RXRX
Q4 25
$42.0M
$1.5B
Q3 25
$45.9M
$1.4B
Q2 25
$39.7M
$1.3B
Q1 25
$38.9M
$1.3B
Q4 24
$34.0M
$1.4B
Q3 24
$33.1M
$726.5M
Q2 24
$34.9M
$775.9M
Q1 24
$37.6M
$557.8M
Debt / Equity
JVA
JVA
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JVA
JVA
RXRX
RXRX
Operating Cash FlowLast quarter
$377.7K
$-46.1M
Free Cash FlowOCF − Capex
$265.4K
$-47.3M
FCF MarginFCF / Revenue
1.0%
-133.1%
Capex IntensityCapex / Revenue
0.4%
3.5%
Cash ConversionOCF / Net Profit
0.47×
TTM Free Cash FlowTrailing 4 quarters
$-5.2M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JVA
JVA
RXRX
RXRX
Q4 25
$377.7K
$-46.1M
Q3 25
$-3.8M
$-117.4M
Q2 25
$-1.2M
$-76.4M
Q1 25
$-401.9K
$-132.0M
Q4 24
$222.0K
$-115.4M
Q3 24
$1.8M
$-59.2M
Q2 24
$-1.2M
$-82.2M
Q1 24
$4.6M
$-102.3M
Free Cash Flow
JVA
JVA
RXRX
RXRX
Q4 25
$265.4K
$-47.3M
Q3 25
$-3.9M
$-117.6M
Q2 25
$-1.2M
$-79.6M
Q1 25
$-419.8K
$-133.8M
Q4 24
$-116.7M
Q3 24
$1.8M
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
JVA
JVA
RXRX
RXRX
Q4 25
1.0%
-133.1%
Q3 25
-16.3%
-2272.5%
Q2 25
-5.0%
-413.9%
Q1 25
-2.0%
-907.4%
Q4 24
-2567.7%
Q3 24
9.4%
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
JVA
JVA
RXRX
RXRX
Q4 25
0.4%
3.5%
Q3 25
0.2%
4.7%
Q2 25
0.1%
16.4%
Q1 25
0.1%
12.4%
Q4 24
28.6%
Q3 24
0.2%
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
JVA
JVA
RXRX
RXRX
Q4 25
0.47×
Q3 25
Q2 25
-1.79×
Q1 25
-0.35×
Q4 24
0.18×
Q3 24
2.90×
Q2 24
Q1 24
13.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons